Athira Pharma Statistics
Total Valuation
Athira Pharma has a market cap or net worth of $16.07 million. The enterprise value is -$12.87 million.
| Market Cap | 16.07M |
| Enterprise Value | -12.87M |
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Athira Pharma has 3.94 million shares outstanding. The number of shares has increased by 1.64% in one year.
| Current Share Class | 3.94M |
| Shares Outstanding | 3.94M |
| Shares Change (YoY) | +1.64% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 12.98% |
| Owned by Institutions (%) | 22.55% |
| Float | 2.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.81, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.81 |
| Quick Ratio | 10.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.80% and return on invested capital (ROIC) is -61.45%.
| Return on Equity (ROE) | -103.80% |
| Return on Assets (ROA) | -49.29% |
| Return on Invested Capital (ROIC) | -61.45% |
| Return on Capital Employed (ROCE) | -177.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.30M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.71% in the last 52 weeks. The beta is 3.02, so Athira Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 3.02 |
| 52-Week Price Change | -15.71% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 3.68 |
| Relative Strength Index (RSI) | 54.48 |
| Average Volume (20 Days) | 31,659 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -57.89M |
| Pretax Income | -59.85M |
| Net Income | -59.85M |
| EBITDA | -56.92M |
| EBIT | -57.89M |
| Earnings Per Share (EPS) | -$15.41 |
Balance Sheet
The company has $29.82 million in cash and $1.02 million in debt, giving a net cash position of $28.81 million or $7.30 per share.
| Cash & Cash Equivalents | 29.82M |
| Total Debt | 1.02M |
| Net Cash | 28.81M |
| Net Cash Per Share | $7.30 |
| Equity (Book Value) | 31.99M |
| Book Value Per Share | 8.11 |
| Working Capital | 29.24M |
Cash Flow
| Operating Cash Flow | -70.70M |
| Capital Expenditures | n/a |
| Free Cash Flow | -70.70M |
| FCF Per Share | -$17.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Athira Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.64% |
| Shareholder Yield | -1.64% |
| Earnings Yield | -375.64% |
| FCF Yield | -443.72% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 18, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Sep 18, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |